Hypofractionated IMRT, prostate cancer, and late toxicities

Hypofractionated radiation therapy for prostate cancer, which shortens the treatment time by about 2.5 weeks and intensifies the dose, has late toxicities comparable to lengthier, less intensive conventional radiation therapy, according to a randomized single-center trial.

MedScape